Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DXP Adjuvant Chemotherapy in Resected Advanced Gastric Cancer
NCT00976976Phase 2Completed
- Sponsor
- Asan Medical Center
- Start
- May 2007
- Primary completion
- Sep 2011
- Modality
- Nanoparticles, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of docetaxel, capecitabine and Cisplatin micelle injection (HA132) in gastric cancer (GC), sponsored by Asan Medical Center. Primary endpoint: Relapse-Free Survival at 5 years. Started May 2007; status: completed.
02
Drugs
docetaxelcapecitabineCisplatin micelle injection (HA132)
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00976976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00976976.